Skip to content
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter
Main Menu
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter

About Me

Nick Mars - Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis. Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Social Icons

Facebook1,750FansLikeX (Twitter)759FollowersFollowInstagram2,500FollowersFollowPinterest1,365FollowersPinYoutube2,700SubscribersSubscribeTiktok2,900FollowersFollowTelegram2,000MembersJoinSoundcloud1,963FollowersFollowVimeo1,254FollowersFollowDribbble3,520FollowersFollow
  • Support
    • Documentation
    • Documentation
    • Video Tutorials
    • Video Tutorials
    • Support Forums
    • Support
  • Support
  • About Theme
  • About theme
  • Visit Us
  • Visit Us
Wednesday, June 24, 2026
Home / Xgeva

Browsing Tag: Xgeva

  • News
  • Regulatory

Health Canada approves Bosaya (denosumab) and Vevzuo (denosumab) by Biocon  

Takeaways:   Bosaya and Vevzuo, layered on top of other recent denosumab biosimilar launches, should accelerate formulary switches and tender competition, strengthen Biocon’s credi...

Arisa Smith
April 21, 2026
Read More

Social Icons

Facebook1,000FansLikeX (Twitter)1,000FollowersFollowInstagram1,000FollowersFollowPinterest1,000FollowersPinYoutube1,000SubscribersSubscribeTiktok1,000FollowersFollowTelegram1,000MembersJoinSoundcloud1,000FollowersFollowVimeo1,000FollowersFollowDribbble1,000FollowersFollow

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis.

Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Email: sample@gmail.com
Call Us: +987 95 95 64 82

Category List

  • Commercial(11)
  • Companies(13)
  • Deals(5)
  • Editor's Pick(5)
  • Latest Updates(1)
  • Manufacturing(6)
  • Must Read(4)
  • News(66)
  • Opinions(30)
  • Public Health(10)
  • R&D(12)
  • Regulatory(38)
  • Technology(8)

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Copyright © 2026 | Powered by News Magazine X